Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D498/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems

Definitions

• the present invention relates to the field of blood coagulation.
• the present invention relates to new oxazolidinone derivatives, processes for their preparation and their use as active ingredients in medicaments.
• Blood coagulation is a protective mechanism of the organism, with the help of which defects in the vascular wall can be quickly and reliably "sealed". In this way, blood loss can be avoided or minimized. Hemostasis after vascular injury occurs essentially through the coagulation system, in which enzymatic cascade of complex reactions triggered by plasma proteins, involving numerous blood coagulation factors, each of which, when activated, converts the next inactive precursor into its active form.
• Fibrinogen to fibrin a fibrous-gelatinous coagulant.
• thrombin is a potent trigger for platelet aggregation, which also makes a significant contribution to hemostasis.
• the maintenance of normal hemostasis - between bleeding and thrombosis - is subject to a complex regulatory mechanism.
• the uncontrolled activation of the coagulation system or a defective inhibition of the activation processes can lead to the formation of local thrombi or embolisms in vessels (arteries, veins, lymphatic vessels) or cardiac cavities. This can lead to serious diseases such as heart attack, angina pectoris (including unstable
• Angina Angina
• reocclusions and restenosis after angioplasty or aortocoro- lead to bypass, stroke, transient ischemic attacks, peripheral arterial disease, pulmonary embolism or deep venous thrombosis; in the following, these diseases are also referred to collectively as thromboembolic diseases.
• hypercoagulability - systemically - can lead to disseminated intravascular coagulation in case of consumption coagulopathy.
• heparin is used for the therapy and prophylaxis of thromboembolic diseases, which is administered parenterally or subcutaneously. Because of its more favorable pharmacokinetic properties, low molecular weight heparin is increasingly preferred these days; However, the known disadvantages described below cannot be avoided in this way either
• heparin is orally ineffective and has a comparatively short half-life. Since heparin inhibits several factors in the blood coagulation cascade at the same time, it has an unselective effect. In addition, there is a high risk of bleeding, in particular brain bleeding and bleeding in the gastrointestinal tract can occur, and it can lead to thrombopenia,
• a second class of anticoagulants are the vitamin K antagonists.
• the compounds can be administered orally, but due to the high risk of bleeding and the narrow therapeutic index, complex individual adjustment and observation of the patient is necessary.
• other side effects such as gastrointestinal disorders, hair loss and skin necrosis are described (Pschyrembel, Klinisches Wörterbuch, 257th edition,
• thromboembolic disorders in the sense of the present invention particularly being used for serious disorders such as Heart attack, angina pectoris
• Another object of the present invention is to provide new anticoagulants which inhibit the blood clotting factor Xa with increased selectivity and which are intended to avoid, at least in part, the problems of the therapy methods known from the prior art for thromboembolic disorders.
• the present invention thus relates to substituted oxazolidinones of the general formula (I)
• R 1 represents optionally benzo-condensed thiophene (thienyl), which may optionally be substituted one or more times;
• R »2 stands for any organic radical
• R, R, R, R, R, R i d R are the same or different and stand for hydrogen or for (-Ce alkyl)
• radical R is an unsubstituted 2-thiophene radical and at the same time the radical R represents a mono- or polysubstituted phenyl radical and at the same time the radicals R 3 , R 4 , R 5 , R 6 ,
• R and R each represent hydrogen.
• R 2 represents one of the following groups:
• the radical "A” stands for (C 6 -C 14 ) aryl, preferably for (C 6 -C 10 ) aryl, in particular for phenyl or naphthyl, very particularly preferably for phenyl;
• the radical "B” for is a 5- or 6-membered aromatic heterocycle which contains up to 3 heteroatoms and / or hetero chain links, in particular up to 2 heteroatoms and / or hetero chain links, from the series S, N, NO (N-oxide) and O contains;
• the radical “D” stands for a saturated or partially unsaturated, mono- or bicyclic, optionally benzo-fused 4- to 9-membered heterocycle which has up to three heteroatoms and / or hetero chain links from the series S, SO, SO 2 , N , Contains NO (N-oxide) and O;
• R 27 , R 28 and R 29 are identical or different and independently of one another are hydrogen, (CC 4 ) alkyl, (C 3 -C 7 ) cycloalkyl, (dC) alkanoyl, carbamoyl, trifluoromethyl, phenyl or pyridyl, and /or
• R 27 and R 28 or R 27 and R 29 together with the nitrogen atom to which they are attached form a saturated or partially unsaturated 5- to 7-membered heterocycle with up to three, preferably up to two identical or different hetero - form atoms from the group of N, O and S, and
• R 30 and R 31 are the same or different and independent of each other
• R 33 (dC ⁇ alkoxy, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl
• Phenyl or acetyl can be substituted, (C 6 -C 14 ) aryl, (C 5 -C 1 o) heteroaryl, trifluoromethyl, tetrahydrofuranyl or butyrolactone,
• R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are the same or different and are for hydrogen or for
• R 1 is an unsubstituted 2-thiophene radical and at the same time the radical R 2 is a mono- or polysubstituted phenyl radical and at the same time the radicals R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each hydrogen.
• R 1 stands for thiophene (thienyl), in particular 2-tbiophene, which can optionally be mono- or polysubstituted by halogen, preferably chlorine or bromine, amino, aminomethyl or (dC ⁇ alkyl, preferably methyl, the (CrC 8 ) -Alkyl radical may in turn optionally be substituted one or more times by halogen, preferably fluorine,
• R 2 represents one of the following groups: AT THE-,
• the radical "A” stands for (C 6 -C 1 ) aryl, preferably for (C 6 -C 1 o) aryl, in particular for phenyl or naphthyl, very particularly preferably for phenyl;
• the radical "B” for one 5- or 6-membered aromatic heterocycle, which contains up to 3 heteroatoms and / or hetero chain links, in particular up to 2 heteroatoms and / or hetero chain links, from the series S, N, NO (N-oxide) and O.
• the radical “D” stands for a saturated or partially unsaturated 4- to 7-membered heterocycle which has up to three heteroatoms and / or hetero-chain links from the series S, SO, SO 2 , N, NO (N-oxide) and
• ⁇ " 5 " 3 "and” D can each optionally be substituted one or more times with a radical from the group consisting of halogen; trifluoromethyl; oxo; cyano; nitro; carbamoyl; pyridyl; (C 1 -C 6 ) alkanoyl; (C 3 -C 7 ) cycloalkanoyl; (C 6 -C 14 ) -
• v means either 0 or 1
• R, R and R are identical or different and, independently of one another, denote hydrogen, (C r C 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, and / or
• R 27 and R 28 or R 27 and R 29 together with the nitrogen atom to which they are attached form a saturated or partially unsaturated 5- to 7-membered heterocycle with up to three, preferably up to two identical or different hetero- form atoms from the group of N, O and S, and
• R 30 and R 31 are the same or different and independent of each other
• radical R 1 is an unsubstituted 2-thiophene radical and at the same time the radical R 2 is a mono- or polysubstituted phenyl radical and at the same time the radicals R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each represent hydrogen.
• R 1 stands for thiophene (thienyl), in particular 2-thiophene, which can optionally be mono- or polysubstituted by halogen, preferably chlorine or bromine, or (dC 8 ) -alkyl, preferably methyl, the (dC 8 ) -
• halogen preferably chlorine or bromine
• (dC 8 ) -alkyl preferably methyl
• the alkyl radical may in turn be substituted one or more times by halogen, preferably fluorine,
• R 2 stands for one of the following groups: A, AM, DMA, BMA,
• the radical "A” stands for phenyl or naphthyl, in particular for phenyl
• the radical "D” stands for a saturated or partially unsaturated 5- or 6-membered heterocycle which has up to two heteroatoms and / or hetero-chain links from the series S, SO, SO 2 , N, NO (N-oxide) and Contains O
• the remainder "M” for -NH-, -O-, -NH-CH 2 -, -CH 2 -NH-, -OCH 2 -, -CH 2 O-,
• R 27 , R 28 and R 29 are the same or different and independently of one another are hydrogen, (dC 4 ) -alkyl or else cyclopropyl, cyclopentyl or cyclohexyl and / or
• R and R or R and R together with the nitrogen atom to which they are attached can form a saturated or partially unsaturated 5- to 7-membered heterocycle with up to two identical or different heteroatoms from the group of N, O and S. , and
• R 30 and R 31 are the same or different and are independently hydrogen, (dC 4 ) alkyl, cyclopropyl, cyclopentyl, cyclohexyl, (dC 4 ) alkylsulfonyl, (dC 4 ) hydroxyalkyl, (dC 4 ) aminoalkyl, di (C 1 -C 4 ) alkylamino- (C 1 -C 4 ) alkyl, (dC 3 ) -
• R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are the same or different and stand for hydrogen or for (dC 6 ) alkyl
• radical R 1 is an unsubstituted 2-thiophene radical and at the same time the radical R 2 is a mono- or polysubstituted phenyl radical and at the same time the radicals R 3 , R 4 , R 5 , R 6 ,
• R 7 and R 8 each represent hydrogen.
• R 1 represents 2-thiophene, which may optionally be substituted in the 5-position by a radical from the group chlorine, bromine, methyl or trifluoromethyl,
• R 2 represents one of the following groups:
• the radical "A” represents phenyl or naphthyl, in particular phenyl
• the radical "B” represents a 5- or 6-membered aromatic heterocycle which contains up to 2 heteroatoms from the series S, N, NO (N -Oxide) and contains O
• the radical "D” stands for a saturated or partially unsaturated 5- or 6-membered heterocycle which has a nitrogen atom and optionally a further hetero atom and / or hetero chain link from the series S, SO, SO 2 and O; or up to two Contains heteroatoms and / or hetero chain links from the series S, SO, SO 2 and O
• the remainder "M” for -NH-, -O-, -NH-CH 2 -, -CH 2 -NH-, -OCH 2 -, -CH 2 O-, -CONH-, -NHCO- or represents a covalent bond;
• v is either 0 or 1, preferably 0, and
• R 27 , R 28 and R 29 are the same or different and independently of one another are hydrogen, (dC 4 ) -alkyl or else cyclopropyl, cyclopentyl or cyclohexyl and / or
• R 27 and R 28 or R 27 and R 29 together with the nitrogen atom to which they are attached form a saturated or partially unsaturated 5- to 7-membered heterocycle with up to two identical or different heteroatoms from the group of N, O and S can form, and
• R 30 and R 31 are the same or different and are independently hydrogen, (-CC 4 ) -alkyl, cyclopropyl, cyclopentyl, cyclohexyl, (dC 4 ) -alkylsulfonyl, (dC 4 ) -hydroxyalkyl, (dC 4 ) - aminoalkyl, Di (C 1 -C 4 ) alkylamino (C 1 -C 4 ) alkyl, (dC 3 ) -
• R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are the same or different and stand for hydrogen or for (-CC 4 ) alkyl
• radical R 1 is an unsubstituted 2-thiophene radical and at the same time the radical R 2 is a mono- or polysubstituted phenyl radical and at the same time the radicals R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each represent hydrogen.
• R 1 represents 2-thiophene which is substituted in the 5-position by a radical from the group chlorine, bromine, methyl or trifluoromethyl,
• R 2 stands for DA-:
• radical "A” stands for phenylene
• radical “D” stands for a saturated 5- or 6-membered heterocycle which is linked via a nitrogen atom to "A”, which has a carbonyl group in the direct vicinity of the linking nitrogen atom and in which a ring carbon member can be replaced by a hetero atom from the series S, N and O;
• the previously defined group “A” in the meta position with respect to the linkage to the oxazolidinone can optionally be mono- or disubstituted with a radical from the group of fluorine, chlorine, nitro, amino, trifluoromethyl, methyl or cyano,
• R 3 , R 4 , R 5 , R 6 , R 7 and R 8 represent hydrogen
• connection with the following is also very particularly preferred
• thienyl optionally benzo-condensed thiophene (thienyl), which may optionally be mono- or polysubstituted by a radical from the group of halogen; cyano; nitro; (dC 8 ) alkyl, which in turn can optionally be substituted one or more times by halogen; (C 3 -C 7 ) cycl
• R 1 represents thiophene (thienyl), in particular 2-thiophene, which may be mono- or polysubstituted by halogen, preferably chlorine or bromine, or (-C-C8) -alkyl, preferably methyl, the (Ci-Cs ) -
• Alkyl radical preferably the methyl radical, may in turn be substituted one or more times by halogen, preferably fluorine.
• R 3 , R 4 , R 5 , R 6 , R 7 and R 8 may be the same or different and in particular for hydrogen or for (dC 6 ) -alkyl, preferably for hydrogen or for (dC) -
• Alkyl very particularly preferably hydrogen.
• the radical R 2 ie the organic radical, can in particular be selected from the substituent groups listed below:
• R 2 in particular represents a group of the following formula:
• n denotes an integer between 0 and 6, preferably between 1 and 3,
• n means either 0 or 1
• p is an integer between 0 and 3, preferably either 0 or 1
• O j represents an integer 0 or 1
• o 2 means an integer 0 or 1
• R 9 and R 10 are the same or different and are hydrogen; (dC 4 ) alkyl, preferably methyl; (dC 4 ) alkoxy, preferably methoxy; (C 3 -C 7 ) cycloalkyl; Are hydroxy or fluorine,
• X and X ' are the same or different and are for O; NR 11 or a covalent bond,
• R 11 is H; (dC 4 ) alkyl, preferably methyl, or (C 3 -C) cycloalkyl,
• Y represents a 3- to 7-membered saturated or partially unsaturated cyclic hydrocarbon radical which optionally contains 1 to 3 identical or different heteroatoms and / or hetero chain links from the group consisting of N, O, S, SO and SO 2 ,
• this radical Y can optionally be substituted by a 5- or 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated cyclic hydrocarbon radical which may optionally contain up to 3 identical or different heteroatoms from the group of N, O and S contains and
• R 12 represents hydrogen, (dC 4 ) alkyl or (C 3 -C 7 ) cycloalkyl
• R 13 and R 13 ' are identical or different and, independently of one another, are hydrogen, (CC 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl
• R 13 and R 13 ' together with the N atom to which they are attached form a 5- to 7-membered heterocycle which can optionally contain up to 2 further heteroatoms from the series N, O and / or S;
• R 14 and R 15 are the same or different and independent of each other
• R 16 and R 17 are identical or different and independently of one another are hydrogen, (dC 4 ) alkyl, (C 3 -C) cycloalkyl or (dC 3 ) alkanoyl;
• R 18 represents hydrogen, (dC 4 ) alkyl or (C 3 -C 7 ) cycloalkyl
• R 19 and R 19 ' are identical or different and independently of one another are hydrogen, (dC) -alkyl or (C 3 -C 7 ) - cycloalkyl and / or R 19 and R 19' together with the N atom to which they are attached are bound to form a 5- to 7-membered heterocycle which may optionally contain up to 2 further heteroatoms from the series N, O and / or S.
• R 2 represents a group of the following formula:
• n an integer between 0 and 3
• n an integer 0 or 1
• O j represents an integer 0 or 1
• o 2 means an integer 0 or 1
• R 9 and R 10 are the same or different and are hydrogen; Methyl;
• X and X ' are the same or different and are for O; NR 11 or a covalent
• R 11 is H or methyl
• Y represents a 5- to 7-membered saturated cyclic hydrocarbon radical which optionally contains 1 or 2 identical or different heteroatoms and / or hetero chain links from the group of N, O, S,
• this radical Y can optionally be substituted by a 5- or 6-membered aromatic or a 5- to 7-membered saturated or partially unsaturated cyclic hydrocarbon radical which optionally contains up to 2 identical or different heteroatoms from the group of N, O and S. and
• R 12 represents hydrogen, methyl, ethyl, cyclopropyl, cyclopentyl or cyclohexyl;
• R 13 and R 13 ' are identical or different and independently of one another are hydrogen, methyl, ethyl, cyclopropyl, cyclopentyl or cyclohexyl and / or
• R 13 and R 13 ' together with the N atom to which they are attached form a 5- to 7-membered heterocycle which can optionally contain up to 2 further heteroatoms from the series N, O and / or S, in particular Piperidinyl, piperazinyl, morpholinyl and thiomolinyl;
• R 14 and R 15 are the same or different and independently of one another are hydrogen, methyl, ethyl, cyclopropyl, cyclopentyl or cyclohexyl or else acetyl;
• R 16 and R 17 are the same or different and are independently hydrogen, methyl, (C 3 -C 7 ) cycloalkyl or acetyl;
• R 18 represents hydrogen, methyl or (C 3 -C 7 ) cycloalkyl
• R 19 and R 19 ' are identical or different and independently of one another are hydrogen, methyl or (C 3 -C) cycloalkyl and / or
• R 19 and R 19 ' together with the N atom to which they are attached form a 5- to 7-membered heterocycle which may optionally contain up to 2 further heteroatoms from the
• Row N, O and / or S can contain, in particular piperidinyl, piperazinyl, morpholinyl and thiomopholinyl.
• R 2 represents a group of the following formula:
• s is an integer between 1 and 6,
• R 20 and R 21 are identical or different and represent hydrogen, (d-C4) -alkyl, (dC 4 ) -alkoxy, (C 3 -C 7 ) -cycloalkyl, hydroxy or fluorine,
• u is either 0 or 1, preferably 0, and
• R 22 , R 23 and R 24 are the same or different and independently of one another are hydrogen, (dC 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, preferably hydrogen or methyl, and / or
• R 22 and R 23 together with the N atom to which they are attached form a 5- to 7-membered heterocycle which may optionally contain up to 2 further heteroatoms and / or hetero-chain links from the series N, O, S, May contain SO and / or SO 2 ;
• R 25 and R 26 are identical or different and independently of one another are hydrogen, (dC 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, preferably hydrogen, methyl or ethyl, where (-C-C) -alkyl and ( C 3 -C) cycloalkyl may in turn optionally be substituted by hydroxy or (dC 6 ) alkoxy.
• R 2 represents one of the following groups: A, AM, DMA, BMA, B,
• the radical "A” stands for (C 6 -C 14 ) aryl, preferably for (C 6 -do) aryl, in particular for phenyl or naphthyl, very particularly preferably for phenyl;
• the radical "B” for a 5- or 6-membered aromatic heterocycle which contains up to 3 heteroatoms and / or hetero chain links, in particular up to 2 heteroatoms and / or hetero chain links, from the series S, N, NO (N-oxide) and O;
• the radical “D” stands for a saturated or partially unsaturated 4- to 7-membered heterocycle which has up to three heteroatoms and / or hetero chain links from the series S, SO, SO 2 , N, NO (N-oxide) and Contains O;
• the radical "M” for -NH-, -CH 2 -, -CH 2 CH 2 -, -O-, -NH-CH 2 -, -CH 2 -NH-, -OCH 2 -,
• v means either 0 or 1
• R 27 , R 28 and R 29 are identical or different and independently of one another are hydrogen, (dC 4 ) -alkyl or (C 3 -C) -cycloalkyl and / or
• R 27 and R 28 or R 27 and R 29 together with the nitrogen atom to which they are attached form a saturated or partially unsaturated 5- to 7-membered heterocycle with up to three, preferably up to two identical or different heteroatoms from the Form group of N, O and S, and
• R 30 and R 31 are the same or different and independent of each other
• radical "A” stands for phenyl or naphthyl, in particular for phenyl
• radical “B” stands for a 5- or 6-membered aromatic heterocycle which contains up to 2 heteroatoms from the series S, N, NO (N -Oxide) and contains O
• radical "D” represents a saturated or partially unsaturated 5- or 6-membered heterocycle which contains up to two heteroatoms and / or hetero-chain links from the series S, SO, SO 2 , N, NO (N-oxide) and O.
• -C (NR 27 R 28 ) NR 29 ; -CONR 28 R 29 ; -SO 2 NR 8 R 29 ; -OH; -NR 30 R 31 ; (dC 4 ) alkyl; and cyclopropyl, cyclopentyl or cyclohexyl,
• v is either 0 or 1, preferably 0, and
• R 27 , R 28 and R 29 are the same or different and independently of one another are hydrogen, (dC 4 ) -alkyl or else cyclopropyl, cyclopentyl or cyclohexyl and / or
• R 27 and R 28 or R 27 and R 29 together with the nitrogen atom to which they are attached form a saturated or partially unsaturated 5- to 7-membered heterocycle with up to two identical or different heteroatoms from the group of N, O and S can form, and
• R 30 and R 31 are the same or different and are independently hydrogen, (dC) -alkyl, cyclopropyl, cyclopentyl, cyclohexyl,
• (dC 4 ) -alkylsulfonyl (dC 4 ) -hydroxyalkyl, (dC 4 ) -aminoalkyl, di- (C 1 -C 4 ) -alkylamino- (C 1 -C 4 ) -alkyl, (C 1 -C 3 ) -Alkanoyl or phenylcarbonyl.
• R 2 represents a group of the following formula: in which
• W stands for S, NH or O, preferably for S.
• R> 2 is a group of the following formula
• R> 2 is a group of the following formula
• oxazohdinones have essentially only been described as antibiotics, occasionally also as MAOIs and fibrinogen antagonists (review: Riedl, B., Endermann, R., Exp. Opin. Ther. Patents 1999, 9 (5), 625), wherein a small 5- [acylaminomethyl] group (preferably 5- [acetylaminomethyl]) seems to be essential for the antibacterial effect.
• Substituted aryl and heteroarylphenyloxazolidinones in which a mono- or polysubstituted phenyl radical may be bonded to the N atom of the oxazolidinone ring and which may have an unsubstituted N-methyl-2-thiophenecarboxamide radical in the 5-position of the oxazolidinone ring, and theirs Use as antibacterial substances are known from US Pat. Nos. 5,929248, 5,801,246, 5,756,732, 5,654,435, 5,654,428 and US Pat. A-5 565 571.
• benzamidine-containing oxazohdinones are known as synthetic intermediates in the synthesis of factor Xa inhibitors or fibrinogen antagonists (WO-A-99/31092, EP-A-623615).
• the compounds of the general formula (I) according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or do not behave like image and mirror image (diastereomers).
• the invention relates both to the enantiomers or diastereomers and to their respective mixtures.
• the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner.
• Shapes are available. This is known to those skilled in the art, and such compounds are also within the scope of the invention.
• Physiologically acceptable, ie pharmaceutically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids.
• Salts with inorganic acids such as, for example, are preferred Hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic or sulfonic acids such as, for example, acetic acid, trifluoroacetic acid, propionic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid or toluenesulfonic acid, benzenesulfonic acid, benzenesulfonic acid, , ,
• salts with customary bases such as alkali metal salts (e.g. sodium or potassium salts), alkaline earth salts (e.g. calcium or magnesium salts) or ammonium salts derived from ammonia or organic amines such as diethylamine, triemylamine,
• hydrates refer to those forms of the compounds of the above general formula (I) which are in the solid or liquid state
• Hydrates are sesquihydrates, monohydrates, dihydrates or trihydrates. Similarly, the hydrates of salts of the compounds according to the invention are also suitable.
• prodrugs refer to those forms of the compounds of the general formula (I) above which can themselves be biologically active or inactive, but which can be converted into the corresponding biologically active form (for example metabohmic, solvolytic or in some other way).
• Halogen stands for fluorine, chlorine, bromine and iodine. Chlorine or fluorine are preferred.
• (CrC 8 ) alkyl stands for a straight-chain or branched alkyl group with 1 to 8 carbon atoms. Examples include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl and n-hexyl.
• the corresponding alkyl groups with fewer carbon atoms, such as (dC 6 ) alkyl and (dC 4 ) alkyl, are derived analogously from this definition. In general, (dC 4 ) -
• Alkyl is preferred.
• Cycloalkyl stands for a cyclic alkyl group with 3 to 7 carbon atoms. Examples include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. The corresponding cycloalkyl groups with fewer carbon atoms, such as, for example, (dd ⁇ cycloalkyl, are derived analogously from this definition. Cyclopropyl, cyclopentyl and cyclohexyl are preferred.
• (C 2 -C 6 ) alkenyl represents a straight-chain or branched alkeny group having 2 to 6 carbon atoms.
• a straight-chain or branched alkeny group having 2 to 4 carbon atoms is preferred. Examples include: vinyl, allyl, isopropenyl and n-but-2-en-1-yl.
• (C 1 -C 8 ) alkoxy represents a straight-chain or branched alkoxy radical with 1 to
• Examples include: methoxy, ethoxy, n-propoxy,
• Mono- or DHd-dV alkylaminocarbonyl stands for an amino group which is linked via a carbonyl group and which has a straight-chain or branched or two identical or different straight-chain or branched alkyl substituents each having 1 to 4 carbon atoms.
• Examples include: methylamino, ethylamino, n-propylarnino, isopropylamino, t-butylamino, N, N-dimethylamino, N, N-diemylamino, N-emyl-N-memylamino, N-melhyl-Nn-propylamino, N-isopropyl-Nn-propylamino and Nt-butyl-N-memylamino.
• (C t -C ⁇ alkanoyl stands for a straight-chain or branched alkyl radical having 1 to 6 carbon atoms, which carries a double bonded oxygen atom in the 1 position and is linked via the 1 position. Examples include: formyl, acetyl, propionyl , n-butyryl, i-butyryl, pivaloyl, n-hexanoyl
• the corresponding alkanoyl groups with fewer carbon atoms such as (d-C5) -alkanoyl, (dC 4 ) -alkanoyl and (C 1 -C 3 ) -Alkanoyl In general, (dC 3 ) -alkanoyl is preferred.
• Cycloalkanoyl stands for a cycloalkylene group with 3 to 7 carbon atoms as defined above, which is linked via a carbonyl group.
• Alkanoyloxymethyloxy radical with 1 to 6 carbon atoms For example called: acetoxymethyloxy, propionoxymethyloxy, n-butyroxymethyloxy, i-butyroxymethyloxy, pivaloyloxymethyloxy, n-hexanoyloxymethyloxy.
• the corresponding alkanoyloxymethyloxy groups with fewer carbon atoms such as (C 1 -C 3 ) alkanoyloxymethyloxy, are derived analogously from this definition. In general, (C 1 -C 3 ) alkanoyloxymethyloxy is preferred.
• (C 6 -C 14 ) aryl represents an aromatic radical having 6 to 14 carbon atoms. Examples include: phenyl, naphthyl, phenanthrenyl and anthracenyl.
• the corresponding aryl groups with fewer carbon atoms, such as (C 6 -do) aryl, are derived analogously from this definition.
• Aryl is preferred.
• (C5-C 1 o) heteroaryl or a 5- to 10-membered aromatic heterocycle having up to 3 heteroatoms and / or hetero chain members from the series S, O, N and / or NO (N-oxide) represents a mono- or bicyclic heteroaromatics, which is linked via a ring carbon atom of the heteroaromatic, optionally also via a ring nitrogen atom of the heteroaromatic.
• Examples include: pyridyl,
• 5- or 6-membered aromatic heterocycles such as e.g. Pyridyl, pyridyl-N-oxide, pyrimidyl, pyridazinyl, furyl and thienyl are preferred.
• a 3- to 9-membered saturated or partially unsaturated, mono- or bicyclic, optionally benzo-condensed heterocycle with up to 3 heteroatoms and / or heterochaines from the series S, SO, SO 2 , N, NO (N-oxide) and / or O represents a heterocycle which may contain one or more double bonds, which may be mono- or bicyclic, in which a benzene ring may be fused to two adjacent ring carbon atoms and which is linked via a ring carbon atom or a ring nitrogen atom.
• Examples include: Tekahydrofuryl, pyrrolidinyl, pyrrolinyl, piperidinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, piperazinyl, morpholinyl, morpholinyl-N-oxide, thiomorpholinyl, azepinyl,
• the corresponding cycles with a smaller ring size e.g. 5- to 7-membered cycles.
• the present invention also relates to a process for the preparation of the compounds of the general formula (I) according to the invention, wherein either according to a process alternative
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 have the meanings given above,
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are those given above
• Suitable solvents for the processes described above are organic solvents which are inert under the reaction conditions. These include halogenated hydrocarbons such as dichloromethane, trichloromethane, tekachloromethane, 1,2-dichloroethane, trichloroethane, tetrachloroethane, 1,2-dichloroethylene or trichlorethylene, ethers such as diethyl ether, dioxane, tefrahydrofuran, glycol dimethyl ether or diethyl methanol, alkylene glycol dimethyl ether Ethanol, n-propanol, iso-propanol, n-butanol or tert-butanol, hydrocarbons such as benzene, xylene, toluene, hexane or cyclohexane, dimethylformamide, dimethyl sulfoxide, acetonitrile, pyridine, hexa
• reagents usually used for this purpose are suitable as activation or coupling reagents for the processes described above.
• bases are suitable as bases.
• bases preferably include alkali metal hydroxides such as sodium or potassium hydroxide or alkali metal carbonates such as sodium or potassium carbonate or sodium or potassium methoxide or sodium or potassium ethoxide or potassium tert-butoxide or amides such as sodium amide, lithium bis (trimethylsilyl) amide or lithium diisopropylamide or amines such as triethylamine, diisopropylethylamine, diisopropylamine, 4-N, N-dimethylaminopyridine or pyridine.
• alkali metal hydroxides such as sodium or potassium hydroxide or alkali metal carbonates such as sodium or potassium carbonate or sodium or potassium methoxide or sodium or potassium ethoxide or potassium tert-butoxide
• amides such as sodium amide, lithium bis (trimethylsilyl) amide or lithium diisopropylamide or amines such as triethylamine, diisopropyle
• the base can be used in an amount of 1 to 5 mol, preferably 1 to 2 mol, based on 1 mol of the compounds of the general formula (II).
• the reactions generally take place in a temperature range from -78 ° C. to the reflux temperature, preferably in the range from 0 ° C. to the reflux temperature.
• the reactions can be carried out at normal, elevated or reduced pressure (e.g. in the range from 0.5 to 5 bar). Generally one works at normal pressure.
• Suitable selective oxidizing agents for the preparation of the epoxides and for the oxidation to sulfone, sulfoxide or N-oxide which may be carried out are m-chloroperbenzoic acid (MCPBA), sodium meta-periodate, N-methylmorpholine-N-oxide (NMO) and monoperoxyphthalic acid or osmium tekoxid in Bekacht.
• the compounds of the general formulas (II), (III), (TV) and (VI) are known per se to the person skilled in the art or can be prepared by customary methods.
• oxazohdinones in particular the 5- (axninomethyl) -2-oxooxazolidines required, cf. WO-A-98/01446; WO-A-93/23384; WO-A-97/03072; J.A. Tucker et al., J. Med. Chem. 1998, 41, 3727; S. J. Brickner et al., J. Med. Chem. 1996, 39, 673; W. A. Gregory et al., J. Med. Chem. 1989, 32, 1673.
• the compounds of the general formula (I) according to the invention have an unforeseeable, valuable pharmacological activity spectrum and are therefore particularly suitable for the prophylaxis and / or treatment of diseases.
• the “thromboembolic diseases” in the sense of the present invention include, in particular, serious diseases such as heart attack, angina pectoris (including unstable angina), reocclusions and restenosis after angioplasty or aortocoronary bypass, stroke, canadian ischemic attacks, peripheral arterial occlusive diseases or deep venous embolism thromboses.
• the compounds of the general formula (I) according to the invention - including also the compounds excluded from chemical protection by disclaimer - are equally suitable for the treatment of disseminated incavascular coagulation (DIC).
• the compounds of general formula (I) according to the invention - including also the compounds excluded from substance protection by disclaimer - are also used for the prophylaxis and / or treatment of atherosclerosis and arthritis, and also for prophylaxis and / or
• inhibitors of the blood coagulation factor Xa are referred to as "selective" in which the IC5 0 values for the factor Xa
• Inhibition against the IC 50 values for the inhibition of other serine proteases, in particular thrombin, plasmin and trypsin, are 100 times, preferably 500 times, in particular 1,000 times smaller, with regard to the test methods for selectivity Reference is made to the test methods of Examples A1) al) and a.2) described below.
• the compounds of the general formula (I) according to the invention - including the compounds excluded from chemical protection by disclaimer - can also be used to prevent coagulation ex vivo, e.g. for preserved blood or biological samples containing factor Xa.
• the present invention thus relates to oxazohdinones of the formula (I) which, in particular, bring about an unexpected, strong and selective inhibition of factor Xa, and this also applies to the compounds excluded from chemical protection by disclaimer.
• the present invention thus furthermore also relates to pharmaceuticals and pharmaceutical compositions which contain at least one compound of the general formula (I) according to the invention together with one or more pharmaceutically acceptable auxiliaries or excipients and can be used for the aforementioned indications.
• the present invention relates to a method for the prophylaxis and / or treatment of diseases of the human or animal body, in particular the aforementioned diseases, using the compounds of the general formula (I) according to the invention - including also the compounds excluded from substance protection by disclaimer.
• the present invention also encompasses a method for preventing blood coagulation in vitro, in particular in the case of preserved blood or biological samples which contain factor Xa, which is characterized in that compounds of the general formula (I) - including also those compounds which are excluded from chemical protection by disclaimer - be added.
• all customary forms of application come into consideration. It is preferably administered orally, lingually, sublingually, buccally, rectally or parenterally (i.e. bypassing the intestinal cactus, that is to say by incavenous, inca-artery, incacardial, incacutaneous, subcutaneous, candermal, incaperitoneal or incamuscular). Oral and incavenous administration are particularly suitable. Oral application is very particularly preferred, in which there is a further advantage over the therapy of thromboembolic disorders known from the prior art.
• the new active compounds of the general formula (I) can be converted in a known manner into the customary formulations, such as tablets, dragées, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable Carriers or solvents.
• the therapeutically active compound should be present in a concentration of about 0.1 to 95% by weight, preferably 0.5 to 90% by weight, in particular 1 to 85% by weight, of the total mixture, ie in amounts sufficient to reach the specified dosage level.
• the formulations are prepared, for example, by masking the active ingredients with solvents and / or carriers, if appropriate using emulsifiers and / or dispersants, e.g. in the case of the use of water as a diluent, organic solvents can optionally be used as auxiliary solvents.
• the compounds of the general formula (I) according to the invention - including also the compounds excluded from chemical protection by disclaimer - are distinguished from conventional preparations for the treatment of thromboembolic disorders in particular in that the selective inhibition of
• Factor Xa a greater therapeutic breadth is achieved. This means a lower risk of bleeding for the patient and better adjustability of the patient for the attending physician. In addition - due to the mechanism - there is a quick onset of action. Above all, however, the compounds according to the invention allow oral administration, which is a further advantage of therapy with the compounds according to the invention.
• the particularly advantageous biological properties of the compounds according to the invention can be determined by the following methods.
• the enzymatic activity of human factor Xa was measured by the implementation of a chromogenic subskate specific for the FXa.
• the factor Xa cleaves from the chromogenic subskate p-nikoaniline. The determinations were carried out in microtiter plates as follows.
• test substances were dissolved in different concentrations of DMSO and for 10 minutes with human FXa (0.5 nmol / l dissolved in 50 mmol / l Tris buffer
• the chromogenic subscate (150 ⁇ mol / 1 Pefachrome® FXa from Pentapharm) was then added. After an incubation period of 20 minutes at 25 ° C., the absorbance at 405 nm was determined. The extinctions of the test approaches with
• test substances were examined for their inhibition of other human serine proteases such as thrombin, trypsin, plasmin.
• thrombin 75 mU / ml
• Chromozym Plasmin® from Boehringer Mannheim
• the anticoagulant effect of the test substances was determined in viko in human plasma.
• human blood was drawn using a 0.11 molar sodium cicate solution as a template in a sodium cicate / blood mixing ratio of 1/9.
• the blood was mixed well immediately after collection and centrifuged at about 2000 g for 10 minutes. The supernatant was pipetted off.
• the prothrombin time (PT, synonyms: thromboplastin time, quick test) was determined in the presence of varying concentrations of test substance or the corresponding solvent using a commercially available test kit (Neoplastin® from Boehringer Mannheim).
• the test compounds were incubated with the plasma at 37 ° C. for 10 minutes.
• Fasted male rats (strain: HSD CPB: WU) weighing 200-250 g were anesthetized with a Rompun / Ketavet solution (12 mg / kg / 50 mg / kg). Thrombus formation was carried out in an arteriovenous shunt based on the method described by Christopher N. Berry et al, Br. J. Pharmacol. (1994), 113, 1209-1214 triggered the method described. To this end, the left jugular vein and the right carotid artery were dissected. An extracorporeal shunt was placed between the two vessels using a 10 cm long polyethylene tube (PE 60). The middle of this polyethylene tube was bound in a further 3 cm long polyethylene tube (PE 160), which contained a roughened nylon thread and a loop to create a thrombogenic surface. The ex-corporeal
• test substances were administered either to animals awake via the tail vein or orally using a pharyngeal tube.
• mice Male fasting rats (strain: HSD CPB: WU) were anesthetized as described above. The rats weighed approximately 200 g on average. The left carotid artery was dissected (approx. 2 cm). The formation of an arterial thrombus was caused by a mechanical vascular injury based on that of K. Meng et al., Naunyn-Schmiedeberg's Arch. Pharmacol. (1977), 301, 115-119. For this purpose, the free carotid artery was disconnected from the blood flow, cooled to -12 ° C in a metal channel for 2 minutes and used to standardize the
• the proximal clamp was removed, the wound was closed and opened again after 4 hours to remove the injured section of the vessel.
• the wet weight of the thrombi was determined immediately.
• the test substances became too was administered either by incavenous route through the tail vein or orally by wakeful animals.
• mice Male fasting rats (strain: HSD CPB: WU) were anesthetized as described above. The rats weighed approximately 200 g on average. The left jugular nena was dissected (approx. 2 cm). The formation of a venous thrombus was caused by a mechanical vascular injury based on that of K. Meng et al., ⁇ aunyn-Schmiedeberg's Arch. Pharmacol. (1977), 301, 115-119. For this purpose, the nena jugularis was disconnected from the blood flow, cooled in a metal channel to -12 ° C for 2 minutes and compressed to a weight of 200 g to standardize the thrombus size. The blood flow was reopened and the wound closed.
• test substances were administered either to animals awake via the tail vein or orally using a pharyngeal tube.
• the substituted anilines can be obtained, for example, by reacting 4-fluoronitrobenzene, 2,4-difluoronicobenzene or 4-chloronobenzene with the corresponding amines or amides in the presence of a base.
• Pd catalysts such as Pd (OAc) 2 / DPPF / NaOt-Bu (Tekahedron Lett. 1999, 40, 2035) or copper (Renger, Synthesis 1985, 856; Aebischer et al., Heterocycles 1998 , 48,2225) happen.
• halogen aromatics without a nico group can first be converted into the corresponding amides in order to then nitrate them in the 4-position (US3279880).
• MS (rI%) 222 (74, M + ), 193 (100), 164 (28), 150 (21), 136 (61), 117 (22), 106 (24), 90 (37), 76 (38), 63 (32), 50 (25)
• the purification can also be carried out by chromatography on silica gel with hexane / ethyl acetate.
• MS (rI%) 192 (100, M + ), 163 (48), 133 (26), 119 (76), 106 (49), 92 (38), 67 (27), 65 (45), 52 (22), 28 (22)
• the nico compound is dissolved in methanol, ethanol or ethanol / dichloromethane mixtures (0.01 M to 0.5 M solution), palladium on carbon (10%) is added and the mixture is stirred overnight under hydrogen at normal pressure. Then it is filtered and concentrated.
• the crude product can be purified by chromatography on silica gel (dichloromethane / ethanol mixtures) or preparative reversed-phase HPLC (acetone / water mixtures).
• iron powder can also be used as the reducing agent.
• the nica compound is dissolved in acetic acid (0.1 M to 0.5 M solution) and at 90 ° C six equivalents of iron powder and water (0.3 to 0.5 times the volume of acetic acid) are added in portions within 10-15 min. After a further 30 min at 90 ° C., the mixture is filtered and the filtrate is concentrated. The arrears with
• the amide is dissolved in DMF and 1.5 equivalents of potassium tert-butoxide are added. The mixture is stirred for 1 h at RT, then 1.2 equivalents of 1-fluoro-4-nicobenzene are added in portions. The reaction mixture is stirred at RT overnight, diluted with ether or ethyl acetate and washed with sat. aq. Washed sodium bicarbonate solution. The organic phase is knocked over magnesium sulfate, filtered and concentrated. The crude product can be purified by chromatography on silica gel (dichloromethane / ethanol mixtures).
• the nica compound is dissolved in ethanol (0.01 M to 0.5 M solution), palladium-on-carbon (10%) is added and the mixture is stirred overnight under normal pressure of hydrogen. Then it is filtered and concentrated.
• the crude product can be purified by chromatography on silica gel (dichloromethane / ethanol mixtures) or preparative reversed-phase HPLC (acetone / water mixtures).
• iron powder can also be used as the reducing agent.
• the nico compound is dissolved in acetic acid (0.1 M to 0.5 M solution) and at 90 ° C six equivalents of iron powder and water (0.3 to 0.5 times the volume of acetic acid) are added in portions within 10-15 min. After a further 30 min at 90 ° C., the mixture is filtered and the filtrate is concentrated. The residue is worked up excactively with ethyl acetate and 2N sodium hydroxide solution. The organic phase is cooled over magnesium sulfate, filtered and concentrated. The crude product can be purified by chromatography on silica gel (dichloromethane / ethanol mixtures) or preparative reversed-phase HPLC (acetone / water mixtures). The following starting compounds were prepared in an analogous manner:
• Example 12 is obtained by reacting Example 12 with trifluoroacetic acid in methylene chloride.
• IC 50 value 140 nM; 1H-NMR [d ⁇ -DMSO]: 3.01-3.25 (m, 8H), 3.5-3.65 (m, 2H), 3.7-3.9 (m, IH), 4.05-4.2 (m, IH), 4.75-4.9 (m , IH), 7.05-7.25 (m, 3H), 7.5 (dd, IH), 7.7 (d, IH), 8.4 (broad s, IH), 9.0 (t, IH).
• chlorothiophene-2-carboxylic acid is 5-chloro-N - ( ⁇ (5S) - 2-oxo-3- [4- (2-oxo-l-pyrrolidinyl) phenyl] -l, 3-oxazolidin-5-yl ⁇ methyl) -2-thiophene-carboxamide.
• Example 17 The individual stages of the previously described synthesis of Example 17 with the respective precursors are as follows:
• the reaction mixture is washed with water and the aqueous phase is extracted again with methylene chloride.
• the combined organic extracts are chopped with MgSO 4 and evaporated.
• the residue (1.67 g) is then dissolved in 70 ml of acetonitrile, mixed with 2.62 g (14.16 mmol) of phthalimide potassium and stirred in a closed vessel in a microwave oven at 180 ° C. for 45 minutes.
• DIEA diisopropylethylamine
• IC 50 90 nM
• the suspension is stirred gently for 2 h, filtered after dilution with dichloromethane DMF (3: 1) (the resin is washed with dichloromethane DMF) and the filtrate is concentrated.
• the product obtained is optionally purified by preparative RP-HPLC.
• the product can be isolated from the reaction mixture by chromatography on silica gel (cyclohexane / ethyl acetate mixtures, dichloromethane / methanol mixtures or dichloromethane / methanol / triethylamine mixtures).
• silica gel cyclohexane / ethyl acetate mixtures, dichloromethane / methanol mixtures or dichloromethane / methanol / triethylamine mixtures.
• a solution of substituted N- (3-amino-2-hydroxypropyl) -5-chloro-2-thiophenecarboxamide derivative (1.0 eq.) In absolute THF (approx. 0.1 mol 1) is carbodiimidazole (1.2 to 1.8 eq.) Or a comparable phosgene equivalent.
• the mixture wkd at room temperature or optionally at elevated temperature (up to 70 ° C) for 2 to 18 h before being concentrated in vacuo.
• the product can be purified by chromatography on silica gel (dichloromethane / methanol mixtures or cyclohexane / ethyl acetate mixtures).
• the following compounds were also prepared via the route of epoxide opening with an amine and subsequent cyclization to the corresponding oxazohdinone:
• the following examples 14 to 16 are exemplary embodiments of the optional, ie optionally occurring, oxidation process step.
• NMO N-Methylmo ⁇ holin-N-oxide
• IC 50 value 210 nM
• Examples 31 to 35 and 140 to 147 relate to the optional, i.e. any amidination process step that takes place.
• the crude product is dissolved in acetone (0.01-0.1 mol / 1) and methyl iodide (40 eq.) Is added.
• the reaction mixture is stirred for 2 to 5 h at room temperature (RT) and then concentrated in vacuo.
• Aqueous trifluoroacetic acid (TFA, approx. 90%) is added dropwise to an ice-cooled solution of a tert-butyloxyca bonyl- (Boc) -protected compound in chloroform or dichloromethane (approx. 0.1 to 0.3 mol / i). After about 15 minutes, the ice cooling is removed and the mixture is stirred at room temperature for about 2-3 hours before the solution is concentrated and knocked in a high vacuum. The residue is taken up in dichloromethane or dichloromethane / methanol and washed with saturated sodium hydrogen carbonate or IN sodium hydroxide solution. The organic phase was washed with saturated sodium chloride solution, over a little magnesium sulfate knocked and concentrated. If necessary, cleaning is carried out by crystallization from ether or ether / dichloromethane mixtures.

Priority Applications (41)

Applications Claiming Priority (2)

Related Child Applications (4)

Publications (2)

Family

ID=7934434

Family Applications (1)

Country Status (50)

Cited By (141)

Families Citing this family (105)

Citations (2)

Family Cites Families (73)

• 1999
  • 1999-12-24 DE DE19962924A patent/DE19962924A1/de not_active Withdrawn
• 2000
  • 2000-11-29 HN HN2000000267A patent/HN2000000267A/es unknown
  • 2000-12-11 US US10/181,051 patent/US7157456B2/en active Active
  • 2000-12-11 KR KR1020077020537A patent/KR20070094672A/ko not_active Application Discontinuation
  • 2000-12-11 DE DE50009607T patent/DE50009607D1/de not_active Expired - Lifetime
  • 2000-12-11 HU HU0203902A patent/HU226522B1/hu active Protection Beyond IP Right Term
  • 2000-12-11 CN CN2006100819193A patent/CN1900074B/zh not_active Expired - Lifetime
  • 2000-12-11 KR KR1020027008172A patent/KR100804932B1/ko active IP Right Review Request
  • 2000-12-11 SI SI200030679T patent/SI1261606T1/xx unknown
  • 2000-12-11 TR TR2002/01636T patent/TR200201636T2/xx unknown
  • 2000-12-11 SI SI200031079T patent/SI1526132T1/sl unknown
  • 2000-12-11 DK DK00993610T patent/DK1261606T3/da active
  • 2000-12-11 CN CNB008189668A patent/CN1262551C/zh not_active Expired - Lifetime
  • 2000-12-11 EP EP00993610A patent/EP1261606B1/de not_active Expired - Lifetime
  • 2000-12-11 IL IL14989600A patent/IL149896A0/xx active Protection Beyond IP Right Term
  • 2000-12-11 DK DK04027037.3T patent/DK1526132T3/da active
  • 2000-12-11 NZ NZ519730A patent/NZ519730A/en not_active IP Right Cessation
  • 2000-12-11 ES ES00993610T patent/ES2237497T3/es not_active Expired - Lifetime
  • 2000-12-11 CZ CZ20022202A patent/CZ301432B6/cs not_active IP Right Cessation
  • 2000-12-11 JP JP2001549389A patent/JP4143297B2/ja not_active Expired - Lifetime
  • 2000-12-11 TR TR2004/01314T patent/TR200401314T2/xx unknown
  • 2000-12-11 WO PCT/EP2000/012492 patent/WO2001047919A1/de active Application Filing
  • 2000-12-11 ES ES04027037.3T patent/ES2457021T3/es not_active Expired - Lifetime
  • 2000-12-11 AT AT00993610T patent/ATE289605T1/de active
  • 2000-12-11 CN CNB2005101271139A patent/CN100549008C/zh not_active Expired - Lifetime
  • 2000-12-11 KR KR1020077008192A patent/KR20070044075A/ko not_active Application Discontinuation
  • 2000-12-11 MX MXPA02006241A patent/MXPA02006241A/es active IP Right Grant
  • 2000-12-11 SK SK908-2002A patent/SK287272B6/sk not_active IP Right Cessation
  • 2000-12-11 DE DE122009000014C patent/DE122009000014I1/de active Pending
  • 2000-12-11 PT PT00993610T patent/PT1261606E/pt unknown
  • 2000-12-11 EE EEP200200341A patent/EE05169B1/xx active Protection Beyond IP Right Term
  • 2000-12-11 BR BRPI0017050-0A patent/BR0017050B1/pt active IP Right Grant
  • 2000-12-11 NZ NZ537058A patent/NZ537058A/en not_active IP Right Cessation
  • 2000-12-11 PT PT40270373T patent/PT1526132E/pt unknown
  • 2000-12-11 CA CA002396561A patent/CA2396561C/en not_active Expired - Lifetime
  • 2000-12-11 AU AU28414/01A patent/AU775126C/en not_active Expired
  • 2000-12-11 SG SG200403830-3A patent/SG130939A1/en unknown
  • 2000-12-11 EP EP04027037.3A patent/EP1526132B1/de not_active Expired - Lifetime
  • 2000-12-11 PL PL355665A patent/PL200413B1/pl unknown
  • 2000-12-11 UA UA2002076161A patent/UA73339C2/uk unknown
  • 2000-12-11 RU RU2002120456/04A patent/RU2297415C2/ru active Protection Beyond IP Right Term
  • 2000-12-11 PL PL382243A patent/PL201121B1/pl unknown
  • 2000-12-18 AR ARP000106733A patent/AR032436A1/es active IP Right Grant
  • 2000-12-19 GT GT200000216A patent/GT200000216A/es unknown
  • 2000-12-20 DO DO2000000114A patent/DOP2000000114A/es unknown
  • 2000-12-20 TW TW083120747A patent/TWI277615B/zh not_active IP Right Cessation
  • 2000-12-20 TW TW089127307A patent/TWI226330B/zh active
  • 2000-12-21 SV SV2000000245A patent/SV2002000245A/es active IP Right Grant
  • 2000-12-22 MY MYPI20006170A patent/MY140488A/en unknown
  • 2000-12-22 PE PE2000001388A patent/PE20010963A1/es not_active IP Right Cessation
  • 2000-12-22 CO CO00097415A patent/CO5251440A1/es active IP Right Grant
• 2002
  • 2002-05-27 ZA ZA200204188A patent/ZA200204188B/en unknown
  • 2002-06-07 CU CU20020114A patent/CU23208A3/es unknown
  • 2002-06-14 BG BG106825A patent/BG65683B1/bg unknown
  • 2002-06-21 MA MA26708A patent/MA25646A1/fr unknown
  • 2002-06-21 NO NO20023043A patent/NO323699B1/no not_active IP Right Cessation
  • 2002-07-23 HR HR20020617A patent/HRP20020617B1/xx not_active IP Right Cessation
• 2004
  • 2004-01-20 HK HK06112529.9A patent/HK1092140A1/xx not_active IP Right Cessation
  • 2004-01-20 HK HK04100440A patent/HK1057556A1/xx not_active IP Right Cessation
  • 2004-10-13 AU AU2004218729A patent/AU2004218729A1/en not_active Withdrawn
  • 2004-10-13 CU CU20040221A patent/CU23423B7/es unknown
  • 2004-12-10 JP JP2004358908A patent/JP5190173B2/ja not_active Expired - Lifetime
• 2006
  • 2006-07-18 HR HRP20060251AA patent/HRP20060251B1/hr not_active IP Right Cessation
  • 2006-07-27 US US11/460,529 patent/US7592339B2/en not_active Expired - Fee Related
• 2007
  • 2007-02-20 NO NO20070981A patent/NO20070981L/no not_active Application Discontinuation
  • 2007-07-17 HK HK07107638.6A patent/HK1103235A1/xx not_active IP Right Cessation
  • 2007-10-31 US US11/932,082 patent/US7576111B2/en not_active Expired - Fee Related
• 2008
  • 2008-01-11 DO DO2008000001A patent/DOP2008000001A/es unknown
  • 2008-02-07 US US12/027,553 patent/US7585860B2/en not_active Expired - Fee Related
  • 2008-11-19 LU LU91497C patent/LU91497I2/xx unknown
  • 2008-11-25 NL NL300370C patent/NL300370I2/nl unknown
  • 2008-12-02 CY CY200800019C patent/CY2008019I1/el unknown
  • 2008-12-04 LT LTPA2008018C patent/LTC1261606I2/lt unknown
  • 2008-12-10 BE BE2008C046C patent/BE2008C046I2/fr unknown
  • 2008-12-11 FR FR08C0051C patent/FR08C0051I2/fr active Active
• 2009
  • 2009-01-08 NO NO2009001C patent/NO2009001I1/no not_active IP Right Cessation
  • 2009-06-30 US US12/494,879 patent/US8129378B2/en not_active Expired - Fee Related
• 2010
  • 2010-04-22 IL IL205242A patent/IL205242A/en unknown
• 2012
  • 2012-01-27 US US13/360,107 patent/US8530505B2/en not_active Expired - Fee Related
  • 2012-06-22 UY UY0001034152A patent/UY34152A/es not_active Application Discontinuation
• 2013
  • 2013-08-07 US US13/961,264 patent/US8822458B2/en not_active Expired - Fee Related
• 2014
  • 2014-05-29 CY CY20141100383T patent/CY1115117T1/el unknown
  • 2014-07-21 US US14/336,379 patent/US20150166568A1/en not_active Abandoned
• 2021
  • 2021-02-25 NO NO2021009C patent/NO2021009I1/no unknown

Patent Citations (2)

Non-Patent Citations (1)